Rapamycin, or Sirolimus, is a metabolite from the bacteria Streptomyces hygroscopicus, and was first discovered in a soil sample of Easter Island. It takes its name from Rapa Nui, the Polynesian name for Easter Island, and -mycin, the suffix for aminoglycoside antibiotic compounds derived from a bacterium, such as Streptomyces. It has been found to have antifungal, anti-proliferative, and immunosuppressive properties. Rapamycin targets the mTOR (mammalian target of rapamycin) signaling pathway, which is in the family of phosphatidylinositol 3-kinase-related kinases and the master regulator of cell growth and metabolism. As such, it has implications in many diseases such as cancer, diabetes, genetic disorders, neurological diseases, and obesity. A primary use for Rapamycin is as an immunosuppressant in organ transplantation.1 Recently, it has also been seen to have a role in increasing lifespan. In mice, its longevity effects have been seen in various ways: in immune system changes, in cancer prevention, in neurological improvements, and more.2 Peptides International is pleased to introduce the versatile inhibitor, Rapamycin, to our product lineup.
- J. Li et al., Cell Metab., 19(3), 373 (2014).
- D. Ehninger et al, Cell Mol Life Sci., 71(22), 4325 (2014).
The entire archive of Peptides International Product Spotlights are available here. The topics range from some of the most popular items we have available to those lesser known ones that still have compelling research applications. They often are chosen due to recently published articles that feature them. They are permanently posted here, so read at your leisure!